Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
12:30pm, Wednesday, 03'rd Jun 2026
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
02:26pm, Thursday, 21'st May 2026
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
BioMarin Reveals Dwarfism Study Data, Stock Soars
02:11pm, Thursday, 21'st May 2026
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stock is trading higher on Thursday as the company is celebrating positive results from its Phase 3 CANOPY-HCH-3 study for VOXZOGO (vosoritide) in children
BioMarin's drug shows significant growth gains in children in late-stage trial
05:20pm, Wednesday, 20'th May 2026
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
04:20pm, Wednesday, 20'th May 2026
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at we
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
02:01pm, Tuesday, 19'th May 2026
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the D
BioMarin's genetic disease therapy shows mixed results in late-stage study
09:24am, Monday, 18'th May 2026
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
09:05am, Monday, 18'th May 2026
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a rem
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
03:48pm, Wednesday, 06'th May 2026
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
02:20pm, Tuesday, 05'th May 2026
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
09:33pm, Monday, 04'th May 2026
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics
08:30pm, Monday, 04'th May 2026
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates
06:20pm, Monday, 04'th May 2026
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.13 per share a year ago.
